Join Dr. David Gonzalez, one of the leading experts in the EuroClonality-NGS working group of the Euroclonality consortium, dedicated to advancing standardized diagnostics in hematology-oncology, to learn:
- How EuroClonality-NDC and Myeloid-NDC NGS Workflows are utilized in advancing
the future of diagnostics, prognostics, and targeted therapies. - How these revolutionary assays provide comprehensive genomic data that reveals
mutations, structural variations, and clonal evolution patterns with remarkable resolution, enabling clinical researchers to delve deeper into the genomic landscape of hematological malignancies.
This on-demand webinar was originally broadcast on March 5, 2026.
What will this webinar empower you to do?
• Understand how the EuroClonality-NDC assay was designed and validated to detect IG/TCR clonality in lymphoid malignancies—along with translocations, small mutations, and copy number variants.
• Achieve integrated genomic profiling of hematological malignancies by combining the Myeloid-NDC with EuroClonality-NDC.
• See how to achieve high accuracy and reproducibility by automating the EuroClonality-NDC workflow on the AVENIO Edge Liquid Handling System.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche. For Research Use Only. Not for use in diagnostic applications. The EuroClonality-NDC and Myeloid-NDC RUO assays are not yet available in the US. AVENIO Edge reagents and workflows are for Research Use Only. They are not intended for diagnostic applications.